© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Emetine Hydrochloride traces its roots back to the early 19th century, when scientists began isolating potent chemical agents from medicinal plants for therapeutic use. Extracted from ipecacuanha root, a plant native to South America, Emetine marked one of the earliest forays into plant-derived alkaloid treatments. Once physicians noticed its powerful action on the gastrointestinal tract, they adopted it mainly for treating amoebic dysentery. European pharmacopoeias recorded it for its reliable emetic qualities, but as the years rolled forward, research proved its value in infectious disease management. National health crises—such as the waves of amoebiasis—pushed for improved formulations and dosing. The story of Emetine echoes the changing approaches to tropical medicine and reflects how necessity drives breakthroughs in pharmaceutical science.
Manufacturers typically supply Emetine Hydrochloride as a crystalline powder or as ready-to-use injectable solutions. Production often operates under strict quality assurance rules, dictated by country-specific pharmacopoeia monographs. Laboratories carefully monitor purity to weed out unwanted plant alkaloids. Product labeling always highlights the stringent shelf-life limits and correct storage conditions—usually in tightly sealed containers, protected from light and moisture. Batch consistency means everything in hospital pharmacies, especially for products with a low therapeutic index. More recently, the expansion into reliable bulk production has supported hospitals and research centers worldwide in their ongoing battle against protozoal infections.
Emetine Hydrochloride presents as a white to off-white crystalline powder, though sometimes a faint yellow tint appears due to minor impurities from the extraction process. Solubility in water remains high, which makes injection formulations practical. It emits a slightly bitter taste and lacks any distinct odor. The molecular formula—C29H40N2O4·HCl—translates to a molar mass just above 500 g/mol. Heat or light can break down the molecule, raising challenges for transport and storage. The compound remains stable under proper conditions, but chemical degradation can occur if it absorbs moisture. It is this clear-cut picture of sensitivity that has guided manufacturers to use amber glass ampoules or resin-lined containers over the years—avoiding unnecessary loss of potency.
Labels for Emetine Hydrochloride go beyond simple drug names. Manufacturers specify precise content—often expressed in percentage or mg/mL for injectable vials. They must also list any preservatives or stabilizers, highlight lot numbers, and include expiry dates. Transport instructions generally call for cool, dark environments. Regulatory agencies in the US, Europe, and select Asian markets enforce tough standards through lot-to-lot testing for purity, residual solvents, and correct pH. Hospitals demand Certificates of Analysis for every purchase, and extra documentation backs up GMP (Good Manufacturing Practice) claims. Several health authorities mandate tamper-evident seals and clear indication of its controlled status, given its toxicity profile.
Manufacturers extract crude Emetine from dried ipecacuanha roots by acid-base precipitation. The plant material is soaked in ethanol or hydrochloric acid solutions to pull out alkaloids, and then filtered to remove plant solids. A series of organic solvent washes follow, gradually isolating the Emetine alkaloid. Treatment with hydrochloric acid produces the desired hydrochloride salt, which is later crystallized and purified through repeated washing. This tried-and-true method sometimes sees upgrades, including chromatography and finer filtration, to keep impurities at bay. Yield depends heavily on the quality of the root stock and the care used during each processing stage; oversight at this level distinguishes pharmaceutical-grade products from rough botanical extracts.
As a naturally occurring alkaloid with two tertiary nitrogen atoms, Emetine serves as a model for basic-structure modifications. Chemists have tinkered with the molecule to improve its pharmacological action or reduce toxicity. Attempts to mask hydroxyl groups or produce methylated derivatives have been recorded in medicinal chemistry literature; some have shown improved selectivity for pathogenic targets over human tissue. The hydrochloride salt remains favored for medical use thanks to its better solubility and injection compatibility. Research sometimes explores analogs combining Emetine with other anti-infective scaffolds, although regulatory approval for these mixtures remains distant. Chemical stability studies dig deep into how light, heat, pH, and counter-ions affect purity—lessons often learned from failed production batches in less controlled environments.
Official texts and research papers list Emetine Hydrochloride under dozens of names, with “methylcephaeline hydrochloride,” “emetinum hydrochloricum,” and “Amarine” seen in specialty compendia. Pharmacies worldwide may recognize it as “Ipecac Alkaloid Hydrochloride,” reflecting its plant-based origin. Trademarked names sometimes appear on older packaging, a legacy from global supply chains that linked South American exporters with European apothecaries. Language variations reflect shifts in preferred Latin, French, or German chemical nomenclature, but pharmacists and clinicians have long favored clear labeling to avoid mixups in busy dispensaries.
No one takes risks with compounds bearing a toxic profile like Emetine Hydrochloride. Staff must handle it in controlled environments—not just for the drug’s sake but to protect themselves. Protective gloves and masks have become standard, especially when compounding injectable solutions. Detailed Safety Data Sheets accompany every shipment, spelling out risks of inhalation, ingestion, or skin exposure, even at low levels. In case of accidental spillage, emergency showers and eyewash stations lie within arm’s reach throughout production spaces. Hospital protocols run constant checks to head off dosing errors: double witnesses during compounding, patient-specific dosing regimens, and clearly articulated adverse-effect monitoring. Few substances teach such a clear lesson about respect for mishandling.
Though developed for its action against amoebic dysentery, uses for Emetine Hydrochloride expanded quickly as researchers learned more about its mechanism inside the body. Most clinicians administer it for severe cases of amoebiasis when newer antiparasitic agents fail or face resistance. Some recent lab work explores its effect on certain types of cancer cells, with mixed results—activity appears, but side effects remain problematic. Researchers in virology circles have examined its antiviral effects on pathogens like Zika and SARS-CoV-2, trying to balance antiviral action with known cardiotoxicity. The agency window for new protocols remains open, yet safety concerns curb hope for routine clinical use in anything but life-threatening infections.
Pharmaceutical R&D teams now pay as much attention to the risks as the benefits of Emetine Hydrochloride, especially in the age of multi-drug resistance. Modern research projects track molecular pathways and off-target effects to redesign analogs that maintain antimicrobial power but shed unwanted toxicity. Advanced cell assays, high-resolution mass spectrometry, and animal models form the backbone of new insight. Drug delivery researchers have worked on liposomal and nanoparticle carriers aimed at delivering lower, less toxic doses to hard-to-reach body sites. Real-world studies, especially those run in resource-limited tropical settings, offer clues for optimization, even as access barriers to reliable supply persist.
The toxicity profile of Emetine Hydrochloride has always generated concern among medical professionals. Overdoses often produce profound nausea and vomiting—ironically, the very effect that gave rise to its name. More serious issues appear with cardiovascular toxicity, including arrhythmias and even fatal heart failure, particularly during repeated or high-dose regimens. Animal studies confirm the risk to heart and liver tissue, and regulatory authorities demand caution in any new trial. Safety watchdog groups continue tracking adverse event reports, and guidelines endorse use only after all other treatments fall short. The margin between therapeutic and toxic doses remains narrow, underscoring why only trained professionals handle administration.
Emetine Hydrochloride stands at a crossroads: proven value against a dwindling list of diseases, persistent toxicological challenges, and new interest from fields like oncology and pandemic virology. Many hope that modern drug design—using structure-guided analog synthesis—will unlock less toxic derivatives. Breakthroughs in targeted delivery might make it safer for longer-term regimens, or transform its application to synergize with modern therapy combinations. With antimicrobial resistance becoming a global crisis, scientists have gone back to the roots—literally—by seeking new uses for old repellents from the plant kingdom. Emetine’s future depends as much on public health urgency as it does on proof of improved safety, with researchers and regulators both pushing for solutions that respect its powerful history and sharp edges.
Emetine hydrochloride often sits under the radar in modern medicine, almost forgotten outside the context of very specific treatments. For a long time, doctors prescribed it for amoebiasis, a nasty infection caused by the parasite Entamoeba histolytica. People pick up this infection mostly in areas lacking clean water and proper sanitation – something many of us in developed countries take for granted. During college, I encountered cases from travelers returning from parts of South America and Asia, and I noticed how quickly the conversation moved to emetine, especially if symptoms became difficult to control.
The real strength of emetine lies in its ability to target amoebae, basically poisoning the parasite’s protein-making machinery. The compound interrupts protein synthesis inside those amoebic cells, eventually killing them. For patients with severe invasive amoebic disease, emetine could mean the difference between life and death before newer therapies arrived on the scene. Still, its use demands close monitoring. Emetine’s toxicity isn’t subtle; too much and it attacks heart muscle and causes other toxic effects, forcing care teams to keep a close eye on dosage and how patients respond.
Some people might think a medication this old lacks value, but public health emergencies sometimes shake up what pharmacists stock and what doctors prescribe. In some countries, newer drugs like metronidazole aren’t always available, or counterfeits flood local markets, pushing doctors back to older options like emetine. Nearly half of deaths from amoebiasis occur in places with limited drug choices. No one wants a community to rely on drugs from the early 1900s, but reality doesn’t always match medical textbooks.
Researchers have been curious about emetine for reasons well beyond amoebae. Lab tests show potential antiviral and anticancer effects, though we don’t see it used much this way yet in clinics. Cancer and infectious disease both push the boundaries of drug research. Sometimes, drugs like emetine re-enter the spotlight, giving hope in cases where nothing else works. You sometimes see this pattern with older antibiotics or antivirals; physicians reach for whatever they believe gives their patient one more option.
Safety always crops up for drugs developed so many years ago. Heart toxicity, in particular, limits routine use. Someone in my hospital once described administering emetine as “walking a tightrope,” referring to the need to balance lifesaving benefits with real risks. A handful of patients with heart disease, pregnancy, or poor kidney function could face life-threatening problems if treated with emetine. Because safer choices exist, pharmacists and infectious disease specialists keep emetine locked away, almost like an emergency tool rather than a frontline solution.
Access gaps remain a tough problem. Rolling out newer, more effective treatments in rural or low-income settings takes money, reliable supply chains, and trust. Local governments and nonprofit organizations sometimes stockpile older medicines out of necessity. Fixing this isn’t about discarding drugs like emetine, but building a bridge to modern therapies and keeping the public informed about why choices matter. It makes a difference when policymakers invest in safer, newer drugs and provide real training for the healthcare workers who deliver them.
Emetine hydrochloride stands as a reminder: medical progress doesn’t just happen; it needs commitment and real-world solutions. The future of treating infectious diseases hinges on making these safer, newer options available—while never forgetting the lessons and value of past medicines.
Emetine hydrochloride draws attention for its place in medicine. Used mainly to treat amoebic infections, the drug has a reputation for strong action. Yet, experience from both patients and clinicians points to a need for caution. Every medicine packs a punch—sometimes the side effects steal the scene from the intended results.
The first signs most folks describe begin in the stomach. Nausea comes up during the first doses. Vomiting often follows, which is no great surprise, given that Emetine once played a role as an emetic. Lining up a meal after taking the drug gets difficult—simple food doesn’t settle. This gut-wrenching routine brings physical weakness, one of those things that drains the day and chips away at recovery.
Muscle pain and soreness in the limbs emerge after a few days. These feelings often creep in with stiffness or a dull ache, not unlike the aftermath of a viral flu. Joints complain and movements start to slow. Like so many medicines that march through the body, emetine hydrochloride often forgets to mind its manners as it goes.
More than anything, the risks to the heart put doctors on alert duty. Emetine does not hide its impact on cardiac fibers. Some people feel palpitations—flutterings that should not be there. An irregular heart rhythm stands out on an EKG. Pulse gets weaker, and breath grows short. Research, such as reports in The New England Journal of Medicine and JAMA, shows these events can take a serious turn. In rare but real cases, the drug paves the way for heart failure, sometimes even after therapy stops. Anyone with old heart problems or pre-existing weakness signals concern from the start.
Liver and kidney function don’t always get the spotlight, though they deserve attention. Blood tests may show enzymes climbing. Most patients don’t feel these inner changes until things get worse, making labs the only warning flag. When nerves take a hit, tingling or numbness in hands and feet creeps up. This neuropathy goes easily unnoticed in the busy world outside the clinic, but it can trouble a person’s routine for weeks.
Living through these side effects brings a messy mix of frustration, worry, and practical challenges. Real life pushes people to work, care for family, and keep routines—even while nausea, weakness, or shortness of breath line the path. Regular medical supervision forms the first shield. Up-to-date ECG checks and blood work become crucial. People taking emetine benefit from open, honest talks with their doctors about every sign and symptom, no matter how small it seems.
Dose matters. Lower and shorter regimens cut risk, as shown in modern guidelines. No one needs a blanket solution—personal health history guides safer decisions. Supporting medications sometimes help settle nausea or protect the heart, though these come with their own baggage. In some places, switching to alternative therapies with fewer risks has become the new order, especially for those with fragile health to begin with.
Informed choice shines as a pillar of care. People deserve a clear view of what they might face—side effects included. Looking at Emetine hydrochloride from both sides reveals the whole picture: a drug that can heal, but needs careful handling and honest conversations every step of the way.
Emetine Hydrochloride stands out in the history of medicine as a strong alkaloid pulled from plants like Cephaelis ipecacuanha. Back in the day, people gave emetine for severe amoebic infections. Emetine isn't something you find in over-the-counter bottles. It's a prescription solution, often reserved for situations where more modern drugs fail or aren’t available.
Doctors typically choose injection—either under the skin or into muscle—for emetine. No sugarcoating: swallowing it by mouth damages the stomach and may not absorb enough to clear the parasite. For those working in infectious diseases, that hard-and-fast rule comes from ugly past experiences—oral dosing can make patients sicker, and the medicine barely works that way. If someone has ever watched a patient with liver pain from amoebas, they know time matters and intravenous forms minimize delays.
Giving emetine is not a DIY undertaking. The margin for safety is narrow. A lot of folks don’t realize how toxic emetine can be—especially to the heart. Medical teams space out doses—usually between five and ten days, rarely longer. They don’t rush, and they stop if signs of heart problems pop up. I once heard a senior physician describe each injection “like walking a tightrope.” He preferred metronidazole, but in rare outbreaks where resistant strains hit, his team dusted off emetine protocols because nothing else worked.
In well-equipped hospitals, nurses track heart rate, watch for vomiting, and run regular ECGs during treatment. If symptoms flare up—shortness of breath, chest pressure, odd heart rhythms—they stop the drug. This real-time monitoring stops small problems from growing into emergencies. There’s a strong lesson in not cutting corners. One patient years ago tried imported “herbal ipecac” after reading an online forum; he nearly died from arrhythmias. Most doctors won’t write prescriptions for emetine outside of very clear, government-certified protocols for just this reason.
Antibiotic resistance is rising. Diseases like amoebic dysentery show up in places with strained health resources. In clinics with scarce supplies, emetine provides a fallback if standard medicine cannot clear the infection. The World Health Organization and leading medical organizations keep dosing guidelines updated and recommend the lowest possible course to bring down the risk of side effects.
Hospitals must train staff in emetine protocols and stress open lines with pharmacists. Electronic health records flag patients for dose errors and potential drug interactions. There’s value in having clear checklists at every injection, especially where junior doctors rotate through infectious disease wards.
Many countries can’t get new-generation anti-amoebic drugs. In places like refugee camps, emetine sometimes plays a vital part in public health. International aid groups and local governments could bulk-purchase and store emetine for emergencies and invest in field training so passing the knowledge torch doesn’t just rely on hand-me-down instructions.
Emetine Hydrochloride means business, best handled by hands that know the risks and the benefits. Shortcutting its administration skips over decades of hard-won lessons and can lead to harm. Strict supervision, steady hands, and real-time patient monitoring reduce risk and give this old drug a continued reason to be stocked when safe alternatives run out.
Doctors rarely reach for Emetine Hydrochloride anymore, but people working in medicine and research know its history as an old remedy for amoebic dysentery and its significant toxicity. The medicine acts as both a strong emetic and as an anti-protozoal, which means it can make someone vomit and it can attack certain parasites. But with those strengths come real risks—you’re not talking about a mild upset stomach here.
Let’s spell it out: Emetine Hydrochloride comes with a laundry list of potential dangers. For folks with any heart issues, it’s trouble. The drug can trigger or worsen heart failure or arrhythmias. Research points to its ability to weaken heart muscle and mess with electrical impulses, so anyone with pre-existing heart disease or who has had a recent heart attack should never be given this drug. The risk just outweighs the benefit.
Anyone with liver or kidney issues faces even bigger problems with Emetine. The body removes this drug through these organs, so if the liver or kidneys aren’t working well, the compound can build up and cause serious toxicity. The effect can show up as muscle weakness, persistent nausea, or severe vomiting that does more harm than help. Sometimes that toxicity also causes nerve damage or lasting muscle problems. The American Journal of Tropical Medicine and Hygiene documents case studies where patients developed severe heart and muscle complications—proving the risk isn’t just rare, but well-known in the medical community.
Pregnant women should avoid Emetine Hydrochloride at all costs. Not only can the drug harm the mother’s organs, it’s also believed to cause birth defects. Studies from the CDC and World Health Organization include warnings for fetal toxicity, making the point clear. This is not a judgment call—a single dose can threaten both lives.
Children’s bodies can’t handle Emetine Hydrochloride the way adult bodies can. Dosing errors and unpredictable effects make it especially unsafe in pediatric settings. Reports show higher incidence of toxic reactions in younger patients, so doctors don’t recommend it for minors under any circumstance.
Doctors left Emetine behind for a reason. Modern medicine offers options with far fewer risks, such as metronidazole for amoebic infections. Those alternatives don’t carry the same dangers for the heart, liver, or nervous system. Still, curiosity remains for rare cases in research, so the question about contraindications keeps popping up in medical circles, especially in settings where newer drugs aren’t always available.
Right now, what matters is protecting patients from avoidable harm. That means choosing safer drugs unless there’s absolutely no alternative and fully disclosing the risks. Regular monitoring and honest communication go a long way—I’ve seen experienced doctors keep their patients alive through tough infections by making careful choices and keeping a close eye on every detail, instead of reaching for shortcuts or risky medicines.
The final point gets simple: don’t use Emetine Hydrochloride in patients with heart disease, pregnancy, liver or kidney impairment, or children. Ethical medicine means taking those lessons seriously, respecting the science, and never assuming that strong medicine means better medicine. The facts keep piling up, and it all goes back to a basic rule—above all, do no harm.
Emetine hydrochloride stands out as an old-school remedy, mostly known for tackling amoebiasis. Its roots stretch back over a century, but it’s rarely used now because safer options exist. This drug didn’t disappear entirely, though—some medical folks have dusted it off for research on viral infections, even in recent studies on COVID-19. Still, anyone who has seen this drug in action, or knows folks who take several prescriptions daily, can’t help but worry about medicines mixing in the bloodstream.
Real-life cases have taught plenty about the dangers of mixing medications. Emetine can be rough on the heart, prolonging the QT interval—basically, how long it takes the heart’s electrical system to reset. Certain antibiotics, antifungals, antiarrhythmics, and antidepressants have the same effect. Taking these together can turn a manageable condition into a heart rhythm emergency.
The threat doesn’t stop there. Emetine’s job is to disrupt protein synthesis inside harmful parasites, but the fallout can hit muscle tissue, too. Combining it with statins or other drugs that stress muscles increases the chance of muscle breakdown—a condition called rhabdomyolysis. This isn’t something to shrug off; muscle pain, weakness, or dark urine call for a visit to the doctor.
In my years of talking to pharmacists and working with patients who line up their pill bottles at home every morning, I’ve learned how easily harmful combinations slip past. Studies published in the Journal of Antimicrobial Chemotherapy and Clinical Infectious Diseases have flagged these same interactions. The FDA database has entries on dangerous cardiac events tied to drug combos involving Emetine.
Doctors lean on digital databases and pharmacists’ keen eyes to sift through a patient’s medication list, but the system isn’t foolproof. One friend taking prescribed medication for arrhythmia shared that his doctor almost missed a prescription interaction, caught only when a pharmacist double-checked the list. The reality is, medication errors hurt thousands every year.
Honest conversations make the difference. It helps to bring an up-to-date list of everything: prescription drugs, over-the-counter products, vitamins, and even herbal teas. Pharmacists care about these lists because some herbal products—think St. John’s wort—ramp up or block drug-metabolizing liver enzymes, which can make Emetine stay in the body longer or disappear too fast.
No one expects patients to keep track of biochemistry at the dinner table, but asking questions pays off. Anyone starting or stopping a medication deserves a quick check-in about changes. Most clinics and pharmacies today use electronic health records, but these only help if the full story is in the system.
Learning about potential interactions is part of managing long-term health. Treatments like Emetine, whether in a hospital setting or an exception to the rule, demand extra care. People living with chronic disease or complex medication regimens benefit from routine medication reviews. Regular, face-to-face checkups with healthcare professionals catch more than machines do.
The safest path weaves through shared information and a team approach. Medical professionals draw on guidelines and experience, and patients provide essential context. As medicine grows more complicated, everyone benefits from asking, “Will this interact with something I already take?” That simple step can keep treatments safer and more effective—even for old medications like Emetine hydrochloride.
| Names | |
| Preferred IUPAC name | methyl (1R,2S,9S,10R,12S,17R,18R)-7,19-dimethoxy-17-[(1S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]-6,8-dioxa-14-azapentacyclo[10.7.1.0²,¹⁰.0⁹,¹⁸.0¹²,¹⁷]nonadeca-3,15,19-triene-1-carboxylate;hydrochloride |
| Other names |
Emetine dihydrochloride Methylcephaeline hydrochloride Emetine HCl Methylcephaeline dihydrochloride |
| Pronunciation | /ˈɛm.ɪˌtiːn haɪˌdrɒk.ləˈraɪd/ |
| Identifiers | |
| CAS Number | 316-42-7 |
| Beilstein Reference | 1364300 |
| ChEBI | CHEBI:4774 |
| ChEMBL | CHEMBL1200328 |
| ChemSpider | 23243583 |
| DrugBank | DB11132 |
| ECHA InfoCard | 100.025.479 |
| EC Number | EC 206-070-6 |
| Gmelin Reference | Gmelin Reference: "175262 |
| KEGG | D07843 |
| MeSH | D003 Emeline Hydrochloride |
| PubChem CID | 441296 |
| RTECS number | XP8040000 |
| UNII | 9T8A298B2K |
| UN number | 2811 |
| Properties | |
| Chemical formula | C29H40N2O4·2HCl |
| Molar mass | 604.16 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.28 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -1.4 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 8.14 |
| Basicity (pKb) | 7.05 |
| Magnetic susceptibility (χ) | -74.5×10⁻⁶ cm³/mol |
| Dipole moment | 4.29 D |
| Thermochemistry | |
| Std enthalpy of combustion (ΔcH⦵298) | -4545 kJ/mol |
| Pharmacology | |
| ATC code | P01CX01 |
| Hazards | |
| Main hazards | Toxic if swallowed, inhaled, or absorbed through skin; causes damage to organs; may cause irritation to skin, eyes, and respiratory tract. |
| GHS labelling | GHS05, GHS06, GHS08 |
| Pictograms | GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P261, P264, P270, P273, P301+P310, P302+P352, P304+P340, P308+P311, P312, P330, P405, P501 |
| NFPA 704 (fire diamond) | 3-3-0 Health:3 Fire:3 Reactivity:0 |
| Lethal dose or concentration | LD50 oral rat 28 mg/kg |
| LD50 (median dose) | LD50 (median dose): **1.2 mg/kg (intravenous, mouse)** |
| NIOSH | KN6800000 |
| PEL (Permissible) | 0.05 mg/m³ |
| REL (Recommended) | 0.02 mg/kg |
| IDLH (Immediate danger) | IDHL: 1 mg/m3 |
| Related compounds | |
| Related compounds |
Cephaeline Psychotrine Oxeladin Isoemetine Methylcephaeline |
